Alyssa Liguori's Archive

Alyssa is a junior Life Sciences major and French minor at Pennsylvania State University. Currently, she tutors chemistry, does biology research on campus, and volunteers at a local hospital. After completing her undergraduate studies, Alyssa hopes to attend medical school. She enjoys working out, reading, drinking coffee, and being outdoors in warm weather.

Alyssa Liguori has written 13 article(s) .

[ by | Jan 29, 2010 12:28 pm | Comments Off ]
Beacon NewsFlashes – January 29, 2009

Panobinostat In Combination With Velcade Shows Potential For Relapsed Multiple Myeloma (ASH 2009) – Researchers presented results at the American Society of Hematology Meeting (ASH) from a Phase 1 clinical trial that show that oral panobinostat (Farydak, LBH589) in combination with intravenous Velcade (bortezomib) has anti-myeloma effects. Researchers tested different doses of both panobinostat (10 mg to 30 mg) and Velcade (1.0 mg/m2 to 1.3 mg/m2). They found frequent blood-related adverse events, such as …

Tags: , , , , , , , , , , , ,
Read the full story »
[ by | Jan 18, 2010 8:00 am | 3 Comments ]
Study Compares Out-Of-Pocket Expenses For Myeloma Patients Treated With Velcade, Revlimid, Or Thalidomide (ASH 2009)

A recent study compared out-of-pocket costs for multiple myeloma patients in the United States being treated with Velcade (bortezomib), Revlimid (lenalidomide), thalidomide (Thalomid), or another chemotherapy or radiation therapy. The results were presented at the American Society of Hematology (ASH) Meeting on December 5.

This study looked at approximately 1,900 multiple myeloma patients who filed claims with a national health insurance company. Researchers looked at out-of-pocket costs for each patient for a period of one year after …

Tags: , , , , , ,
Read the full story »
[ by | Jan 7, 2010 5:57 pm | Comments Off ]
FDA Approves Velcade’s Data Showing Survival Benefit In Newly Diagnosed Myeloma Patients

The United States Food and Drug Administration (FDA) has approved changes to the prescribing information for Velcade (bortezomib), including the addition of long-term data from the VISTA trial showing that Velcade extends survival of newly diagnosed multiple myeloma patients. New dose recommendations for patients with moderate to severe liver damage were also added. The changes were approved in response to a supplemental new drug application (sNDA) submitted by Velcade’s manufacturer, Millennium: The Takeda Oncology Company.

The VISTA trial, …

Tags: , , , ,
Read the full story »
[ by | Dec 29, 2009 10:37 am | Comments Off ]
Addition Of Thalidomide To Induction Therapy Increases Response Rates In Younger And Older Multiple Myeloma Patients (ASH 2009)

Preliminary results from a clinical trial designed to assess the effect of adding thalidomide (Thalomid) to induction therapy prior to autologous stem cell transplantation show that it increases response rates in both young and elderly multiple myeloma patients. These results were presented on December 7th at the 51st American Society of Hematology (ASH) meeting.

A total of 1,970 multiple myeloma patients participated in this trial, which split patients up into two separate groups based on age. The younger patients, …

Tags: , , , , ,
Read the full story »
[ by | Dec 26, 2009 5:24 pm | Comments Off ]
Brand Name:
Generic Name: sotatercept
Code Name: ACE-011
Company: Celgene and Acceleron Pharma
FDA Clinical Phase: 2

Description:

ACE-011 is a human fusion protein from the combination of Activin Receptor Type IIA and an antibody molecule. It is called a fusion protein because scientists have joined …

Tags: , ,
Read the full story »
[ by | Dec 26, 2009 4:57 pm | Comments Off ]
Brand Name: Afinitor
Generic Name: everolimus
Code Name: RAD001
Company: Novartis
FDA Clinical Phase: 1/2

Description:

Afinitor was approved by the FDA in March 2009 for the treatment of advanced renal cell carcinoma, but it is currently also being studied in multiple myeloma. It works by inhibiting …

Read the full story »
[ by | Dec 22, 2009 3:42 pm | One Comment ]
Revlimid Maintenance Therapy Significantly Extends Disease-Free Survival

Preliminary results from a Phase 3 clinical trial show that multiple myeloma patients who received Revlimid (lenalidomide) following a stem cell transplant had a significantly longer period of disease-free survival compared with a placebo group.

The trial (known as CALGB 100104) began with 568 multiple myeloma patients ages 18 to 70 years. No patients had a prior transplant or were treated for myeloma for longer than a year.

All participants received an autologous stem cell transplant, in which their …

Tags: , , ,
Read the full story »